Sinovac Biotech (NSDQ: SVA) was selected to supply its hepatitis A vaccine, Healive®, to the Beijing Expanded Program of Immunization [EPI]. Sinovac was selected one of the two suppliers and was allocated a greater share of the total purchase order.
The decision was made by the Beijing CDC, which evaluated suppliers on the basis of several criteria, including product quality, service and price. The order was for 477,000 doses. As a point of reference, Healive orders for the third quarter of 2009 were almost 1 million.
A hepatitis A vaccine has been part of China’s national immunization program since 2008. The announced goal is to extend vaccination to newborns across the country by the end of 2010.
Healive is Sinovac’s legacy product. The company has expanded its vaccine portfolio by adding vaccines for flu, both seasonal and pandemic, and it is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies.
Disclosure: No positions